2012 represents a period with robust news flow for emerging immuno-oncology companies
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution
September 18, 2011 By Leave a Comment
Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.
Cancer Immunotherapy: A Roundtable Discussion
June 30, 2011 By 3 Comments
Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.
Ipilimumab Approval Highlights Immunotherapy Renaissance
March 25, 2011 By Leave a Comment
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 2 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Follow MD Becker Partners